Please see my rebuttal to Dr. Pasricha's article in the Washington Post. This article is a regurgitation of the 30yr IDSA dogma that ignores all evidence of persistent infection. What makes a gastroenterologist an authorty on Lyme disease? Who spoon-fed her the info for this piece; Dr. Paul Auwaerter?
---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: tpasricha@mgh.harvard.edu
Cc: matt.murray@washpost.com, krissah.thompson@washpost.com, matea.gold@washpost.com, scott.vance@washpost.com, David.Shipley@washpost.com, Mary.Duenwald@washpost.com, Charles.Lane@washpost.com, Stephen.Stromberg@washpost.com
Date: 06/21/2024 9:06 AM EDT
Subject: What the latest science says about Lyme disease
The Washington Post
ASK A DOCTOR
What the latest science says about Lyme disease
https://www.washingtonpost.com/wellness/2024/06/17/can-lyme-disease-be-cured/
Advice by Trisha Pasricha, MD
“We have fairly sufficient evidence about many therapies that do not work for PTLDS. For example, repeated courses of antibiotics are no better than a placebo, an important lesson learned from multiple randomized-controlled trials. This data did not surprise many in the medical community as none of these trials found evidence of residual infection in the first place.”
Trisha Pasricha, MD, MPH, Gastroenterologist
Massachusetts General Hospital
Dear Dr. Pasricha,
In 2001 the NIH funded antibiotic trials for Lyme disease set the stage for treatment denial as no evidence of persistent infection was found in a total of more than 700 different blood and cerebrospinal fluid samples from the 129 patients in these studies but in 2018 all patients were culture positive even after multiple years on antibiotics so there was no relief from current antimicrobials. Some of these patients had taken as many as eleven different types of antibiotics.
In addition, there are 700 peer reviewed publications identifying persistent infection.
So why is all this evidence ignored?
After studying the mishandling of Lyme for the past fifteen years I can say with absolute certainty that the rush to create a vaccine led to the mismanagement of this life altering infection misclassified as “hard to catch and easily treated.”
The following inquiry addressed to Dr. Raymond Dattwyler offers an explanation for why Chronic Lyme must never be recognized. It should be noted that there was no response from Dattwyler who owns 24 patents for Lyme disease that include diagnostic testing and vaccines both live bacteria and oral.
Inquiry to Dr. Raymond Dattwyler:
---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: Raymond_Dattwyler@nymc.edu
Cc: npjvaccines@nature.com, abarrett@utmb.edu, R.W.Titball@exeter.ac.uk, mgomesso@uthsc.edu
Date: 01/06/2023 2:46 PM EST
Subject: The year that shaped the outcome of the OspA vaccine for human Lyme disease
npj Vaccines Jan 2022
The year that shaped the outcome of the OspA vaccine for human Lyme disease
https://www.nature.com/articles/s41541-022-00429-5
Raymond J. Dattwyler & Maria Gomes-Solecki
Department of Microbiology and Immunology
New York Medical College
Valhalla, NY
Raymond J. Dattwyler, Corresponding Author
Dear Dr. Dattwyler,
I read your manuscript with great interest as you call attention to a treatment-resistant Lyme arthritis with “no evidence of DNA” found in the joints of patients after antibiotic treatment.
For some strange reason however, I could not find the following 1995 publication within your paper identifying treatment-resistant neuroborreliosis:
European Neurology 1995
Seronegative Chronic Relapsing Neuroborreliosis
https://www.karger.com/Article/Abstract/117104
Lawrence C., Lipton R.B., Lowy F.D., Coyle P.K.d
Abstract
We report an unusual patient with evidence of Borrelia burgdorferi infection who experienced repeated neurologic relapses despite aggressive antibiotic therapy. Each course of therapy was associated with a Jarisch-Herxheimer-like reaction. Although the patient never had detectable free antibodies to B. burgdorferi in serum or spinal fluid, the CSF was positive on multiple occasions for complexed anti-B. burgdorferi antibodies, B. burgdorferi nucleic acids and free antigen.
In fact, Dr. Dattwyler there seems to be a great deal of “treatment-resistant” evidence published in multiple journals over the past three decades:
Peer Reviewed Evidence of Persistence of Lyme Disease Spirochete Borrelia burgdorferi and Tick-Borne Diseases (700 References)
https://www.dropbox.com/s/n09sk90eo6xz7ua/700%20articles%20LYME%20EvidenceofPersistence-V2.pdf?dl=0
So that brings me to the reason for this email...
Question:
Does a chronic relapsing seronegative disease fit the vaccine model? If not, would that, in and of itself, be the hidden reason for denying chronic (treatment-resistant) Lyme disease for almost three decades? In other words, patent royalties and pharmaceutical profits over lifesaving care?
A response to this inquiry is requested.
Carl Tuttle
Hudson, NH
Cc: Alan D.T. Barrett, PhD Editor-in-Chief
Rick Titball, PhD, DSc, Deputy Editor
Letter to the Editor of the BMJ published June 2020
https://www.bmj.com/content/369/bmj.m1041/rr-1
Dr. Pasricha,
After reading your so-called “advice” on Lyme disease, you strike me as someone who has not questioned the “safe and effective” Covid public health narrative.
Carl Tuttle
Independent Researcher
Hudson, NH